{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of VTE Prophylaxis in Korean Patients Undergoing Gastrectomy"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "The PROTECTOR trial was a randomised controlled trial conducted at Seoul St Mary\u2019s Hospital, South Korea, from August 1, 2011, to March 31, 2015."
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients with histologically confirmed gastric adenocarcinoma were randomised."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive either intermittent pneumatic compression (IPC) alone or IPC plus low-molecular-weight (LMW) heparin sodium."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of VTE within the postoperative period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence with allocation concealment."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applied to patients, clinicians, or outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 682 patients were randomised, with 341 in each group."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "The analysis included 666 patients, using both intention-to-treat and per-protocol approaches."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "VTE incidence was significantly higher in the IPC-only group (3.6%; 95% CI, 2.05%-6.14%) compared to the IPC+LMW heparin group (0.6%; 95% CI, 0.17%-2.18%; P = .008)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Bleeding complications were more frequent in the IPC+LMW heparin group (9.1%) compared to the IPC-only group (1.2%; P < .001)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrials.gov Identifier: NCT01448746"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 20,
    "max_score": 25
  },
  "model": "gpt-4o"
}